Biogen leads structurally, with valuation as the clearest single gap between the two profiles. Sanofi still has the edge on stability, which keeps the comparison from looking entirely one-sided. On the market side, Biogen is in better shape — its trend is intact while Sanofi's trend has broken down. That puts structure and market broadly in agreement — Biogen's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (BIIB: Nasdaq 100, SAN.PA: STOXX 600).
The comparison is mainly decided in valuation, while stability remains the main counterforce.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. BIIB and SAN.PA share the same industry classification.
For a similarity-based comparison, see how Biogen and Sanofi each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing shapes this comparison more than a broad operating gap.
Left means cheaper relative valuation. Higher means stronger structure.
Structure stays fairly close here, while current pricing still looks more supportive for Biogen Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where BIIB and SAN.PA each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a trailing P/E that is 2.4 turns lower.
There is still a strong counterforce in stability, so the lead stays clear without becoming a sweep.
Valuation settles the comparison, while pricing and stability keep the broader setup from looking fully aligned.
Break down the BIIB vs SAN.PA comparison across all dimensions with the full interactive tool.
Explore how BIIB and SAN.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.